We all know vaccines can provide protection against viruses, but they may also help protect us from bacteria and other infections. Bacteria like Neisseria meningitidis, can enter the blood stream and through the thin linings covering the brain and spinal cord which can lead to a rare but serious illness called meningococcal disease. While most survive, some of those who recover from the disease can face long-term side effects like scarring, deafness, seizures or the loss of an arm or leg. In a small number of cases, it can be fatal.

Young adults (those under 25 years) are at increased risk of contracting meningococcal disease due to shared housing arrangements and close contact with friends, roommates and others. Symptoms can start with a headache or fever, similar to a common cold, and can progress rapidly and be potentially life-threatening within 24 hours. 

No vaccine helps protects against all common strains of meningococcal disease. 

AusTrials is conducting a clinical study testing a meningococcal vaccine that combines 5 main strains of the disease (ABCWY) into one vaccine at our locations in Taringa and Tarragindi. The study will involve 6 clinic visits over an 18-month period and 4 vaccine injections.

Eligible participants will receive compensation for time and travel.

You may be eligible to take part if:

  • You are healthy and under the age of 25 years;
  • You have not had a vaccine against any of the 5 meningococcal strains (A,B,C,W or Y). However, you can still join the study if you received a meningococcal C strain vaccine before 24 months of age.

To register your interest in the study please visit AusTrials or phone (07) 3278 5255.